Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic acid plus ursodeoxycholic acid in primary biliary cholangitis
CTR20211354Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in primary biliary cholangitis (PBC) comparing Obeticholic acid + ursodeoxycholic acid with Placebo + ursodeoxycholic acid (2 arms). Primary endpoint: Proportion of PBC patients achieving the composite primary endpoint at last visit. Started Jun 2021; status: completed.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on CTR20211354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211354.